Clinical Trial Update: Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating CKD-397 for efficacy and safety in benign prostatic hyperplasia has completed; the update does not disclose trial results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia

Drugs mentioned

• CKD-397

Snippet

Sponsor: Chong Kun Dang Pharmaceutical | Conditions: Benign Prostatic Hyperplasia | Phase 3 | Status: COMPLETED